Clinical trials located in

Libourne

Libourne city is located in France. Currently, 7 clinical trials are being conducted in this city.

Libourne, nestled at the confluence of the Isle and Dordogne rivers in southwestern France, is a historic city renowned for its wine trade. Founded in the 13th century, it boasts a rich architectural heritage, including the Gothic church of Saint-Jean and the Place Abel Surchamp, a picturesque square surrounded by arcades. The city is a gateway to the prestigious vineyards of Saint-Émilion and Pomerol, making it a key player in the Bordeaux wine region. Libourne’s market, one of the largest in France, reflects its vibrant local culture and gastronomy.

  • CT-EU-00029960

    Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Benralizumab’s impact on severe asthma study

    The study will examine the effects of a drug called benralizumab on people suffering from a severe type of asthma called eosinophilic asthma. Scientists will do this by using special imaging technology called functional airway imaging (FRI) to take pictures of the lungs before and after treatment. It’s an open-label trial, which means everyone knows that the asthma drug under investigation is benralizumab. The study will last from 15 to 23 weeks. Participants in this study must be adults (18 years of age or older), both men and women, who already have severe eosinophilic asthma. Their asthma is not currently well treated with regular inhalers or other asthma medications. One of the goals of the study is to see if benralizumab helps reduce airway resistance and clear mucus in the lungs. Scientists will measure parameters such as lung volume, airway resistance and mucus accumulation.

    • Benralizumab
  • Exploring new asthma treatment for adults

    This clinical trial evaluates londamocitinib (AZD4604), a potential new treatment for adults with moderate-to-severe asthma uncontrolled by standard inhalers (ICS-LABA). Participants will receive AZD4604 or a placebo via a dry-powder inhaler over 12 weeks. The trial aims to assess the drug’s effectiveness in managing asthma symptoms and its safety. It focuses on adults whose asthma is not well-controlled by current medications, seeking to offer a new therapeutic option.

    • londamocitinib/AZD4604
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.